Day: March 29, 2020

Landmark SPYRAL HTN-OFF MED Pivotal Trial Shows Superiority for Renal Denervation in Patients with High Blood Pressure Compared to Sham Procedure

Written by Customer Service on . Posted in Public Companies.

ACC.20/WCC: Study Finds Significant Blood Pressure Reductions Achieved with RDN in Absence of Anti-Hypertensive Medication Medtronic Receives FDA “Breakthrough Device Designation” for Symplicity Spyral™ Renal Denervation SystemDUBLIN, March 29, 2020 (GLOBE NEWSWIRE) —  Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced first-ever clinical data from the SPYRAL HTN-OFF MED Pivotal Trial. The prospectively powered study of patients with uncontrolled high blood pressure (BP) not taking anti-hypertensive medications met its primary and secondary effectiveness endpoints, with a >99.9% probability of superiority for both versus those who received a sham control procedure. Additionally, there were no major device or procedural safety events through three months. The study was presented today as part of the...

Continue reading

Medtronic Evolut TAVR System Demonstrates Excellent Outcomes in Study of Low-Risk Patients with Bicuspid Aortic Stenosis

Written by Customer Service on . Posted in Public Companies.

ACC.20/WCC: Low Rates of Paravalvular Leak and High Survival Observed in Late-breaking Clinical Trial of Low-Risk Bicuspid Aortic Stenosis PatientsDUBLIN, March 29, 2020 (GLOBE NEWSWIRE) —  Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced late-breaking clinical data from the Low Risk Bicuspid Study assessing the use of the Evolut™ transcatheter aortic valve replacement (TAVR) system in patients with bicuspid aortic valve stenosis at low surgical risk. The study showed low rates of all-cause mortality or stroke at 30 days (1.3%) with a low rate of serious procedural complications, and no annular rupture or aortic dissection. The study was presented as part of the American College of Cardiology together with World Congress of Cardiology Scientific Sessions (ACC.20/WCC) meeting.Results from the 150-patient,...

Continue reading

Correction: Regarding decisions of the Supervisory Council

Written by Customer Service on . Posted in Public Companies.

The Company announces decisions made today during the meeting of the Supervisory Council regarding changes in the Management Board and the Supervisory Council. Birutė Čepanskienė, a member of the Management Board and Chief Commercial Officer will be replaced by Ieva Galvydiene starting from 1st April. B. Čepanskienė is leaving the Board due to personal circumstances.I. Galvydienė has great experience in the tourism industry, especially in sales and commerce. She has been with the Novaturas Group for 13 years and has been leading the Sales department in Lithuania for 8 years, also coordinating commerce in other markets. Since November 2019, I. Galvydienė has been heading the Aviation Division at Novaturas Group. The Company continues to follow the strategy of having long-term executives with excellent know-how, multiple years of experience...

Continue reading

Correction: Dėl stebėtojų tarybos sprendimų

Written by Customer Service on . Posted in Public Companies.

Bendrovė praneša apie šiandien vykusiame Stebėtojų tarybos posėdyje priimtus sprendimus dėl pokyčių valdyboje ir stebėtojų taryboje.Bendrovės valdybos narę Birutę Čepanskienę nuo balandžio 1 d. keičia Ieva Galvydienė. B. Čepanskienė valdybą palieka dėl asmeninių aplinkybių. I. Galvydienė nuo balandžio 1 d. perims ir „Novaturo“ grupės Komercijos vadovės pareigas.I Galvydienė yra sukaupusi daug turizmo industrijos patirties, ypač – pardavimų, komercijos srityse. „Novaturo“ grupėje ji dirba jau 13 metų, 8-erius iš jų vadovavo Pardavimų skyriui Lietuvoje, koordinavo pardavimus kitose rinkose. Nuo praėjusių metų lapkričio I. Galvydienė vadovauja „Novaturo“ grupės Aviacijos skyriui.Įmonė ir toliau laikosi strategijos, kad bendrovės valdyboje dirbtų ilgamečiai įmonės vadovai, sukaupę daug praktinių žinių, daugybės metų patirtį turizmo rinkoje...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.